Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | Chief Medical Officer | June 08, 2020 | June 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRECISION BIOSCIENCES INC
Report date June 08, 2020 · Filed June 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.21 · Expires 2030-06-07 | Direct | 133,206 |
Reported balance
After 2020-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-08 · Grant · Acquired 133,206 · Balance 133,206 F1: The option vests as to 25% of the underlying shares on April 1, 2021 and vests in equal installments at the end of each successive three-month period over the 36 months following such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the underlying shares on April 1, 2021 and vests in equal installments at the end of each successive three-month period over the 36 months following such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Arcellx, Inc.
Report date April 28, 2026 · Filed April 28, 2026
Section 16 reporting ended · disclosed 2026-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 1
1 source rowRow 1 · 2026-04-28 · Other · Disposed 23,749 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.28 · Expires 2031-06-09 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-28 · Disposition to issuer · Disposed 10,901 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.28 · Expires 2031-06-09 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-28 · Disposition to issuer · Disposed 43,604 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2032-02-03 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-28 · Disposition to issuer · Disposed 132,416 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.97 · Expires 2032-09-28 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-28 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.03 · Expires 2033-01-03 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-28 · Disposition to issuer · Disposed 76,242 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.15 · Expires 2034-01-02 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-28 · Disposition to issuer · Disposed 60,096 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-28 · Disposition to issuer · Disposed 13,021 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Company Common Stock. F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-28 · Disposition to issuer · Disposed 39,194 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Company Common Stock. F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-28 · Disposition to issuer · Disposed 67,708 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Company Common Stock. F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger. |
| Performance-based Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 45,138 |
Reported balance
After 2026-04-28 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-04-28 · Grant · Acquired 45,138 · Balance 45,138 F3: Each restricted stock unit represents a contingent right to receive one share of Company Common Stock. F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger. |
| Performance-based Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-04-28 · Disposition to issuer · Disposed 45,138 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Company Common Stock. F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.
F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger.
F3: Each restricted stock unit represents a contingent right to receive one share of Company Common Stock.
F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Closing Amount, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger (with the number of shares underlying any Company RSUs that were subject to performance-based vesting conditions determined based on achievement of actual performance in connection with the Merger, as determined by the Company's board of directors or a committee thereof), and (ii) one (1) CVR for each share subject to such Company RSU immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2023 Filed May 8, 2023 22:50 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,200 | $45.00 | $54,002.04 |
DisclosureSEC source: 0001209191-23-028107 · doc4.xml · nonDerivative · entry 1 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,492 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 1,200 shares sold in the price range of $45.00 to $45.02 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:10 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027653 · doc4.xml · derivative · entry 4 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,205 Underlying: Common Stock · 3,000 shares Expires 2032-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:10 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 2,600 | $43.56 | $113,243.26 |
DisclosureSEC source: 0001209191-23-027653 · doc4.xml · nonDerivative · entry 3 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,692 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022. F3 · price: Represents the weighted average share price of an aggregate total of 2,600 shares sold in the price range of $43.21 to $43.78 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:10 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 400 | $42.72 | $17,086.00 |
DisclosureSEC source: 0001209191-23-027653 · doc4.xml · nonDerivative · entry 2 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,292 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 400 shares sold in the price range of $42.09 to $43.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:10 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 3,000 | $15.00 | $45,000.00 |
DisclosureSEC source: 0001209191-23-027653 · doc4.xml · nonDerivative · entry 1 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 20:11 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025669 · doc4.xml · derivative · entry 5 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,205 Underlying: Common Stock · 10,000 shares Expires 2032-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 20:11 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001209191-23-025669 · doc4.xml · derivative · entry 4 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,623 Underlying: Common Stock · 10,000 shares Expires 2031-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 20:11 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 20,000 | $40.00 | $800,068.00 |
DisclosureSEC source: 0001209191-23-025669 · doc4.xml · nonDerivative · entry 3 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,692 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 20,000 shares sold in the price range of $40.00 to $40.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 20:11 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 10,000 | $15.00 | $150,000.00 |
DisclosureSEC source: 0001209191-23-025669 · doc4.xml · nonDerivative · entry 2 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 20:11 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 10,000 | $6.28 | $62,800.00 |
DisclosureSEC source: 0001209191-23-025669 · doc4.xml · nonDerivative · entry 1 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2023 Filed Apr 20, 2023 20:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 9,745 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024979 · doc4.xml · derivative · entry 10 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,205 Underlying: Common Stock · 9,745 shares Expires 2032-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022. Read SEC document |
| April 19, 2023 Filed Apr 20, 2023 20:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 2,600 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001209191-23-024979 · doc4.xml · derivative · entry 9 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,623 Underlying: Common Stock · 2,600 shares Expires 2031-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021. Read SEC document |
| April 19, 2023 Filed Apr 20, 2023 20:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 15,642 | $35.01 | $547,660.83 |
DisclosureSEC source: 0001209191-23-024979 · doc4.xml · nonDerivative · entry 6 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,692 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 15,642 shares sold in the price range of $35.00 to $35.17 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 19, 2023 Filed Apr 20, 2023 20:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 9,745 | $15.00 | $146,175.00 |
DisclosureSEC source: 0001209191-23-024979 · doc4.xml · nonDerivative · entry 5 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2023 Filed Apr 20, 2023 20:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 2,600 | $6.28 | $16,328.00 |
DisclosureSEC source: 0001209191-23-024979 · doc4.xml · nonDerivative · entry 4 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 20:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 2,400 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024979 · doc4.xml · derivative · entry 8 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,950 Underlying: Common Stock · 2,400 shares Expires 2032-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 20:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001209191-23-024979 · doc4.xml · derivative · entry 7 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,223 Underlying: Common Stock · 3,000 shares Expires 2031-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 20:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 6,000 | $35.00 | $210,000.00 |
DisclosureSEC source: 0001209191-23-024979 · doc4.xml · nonDerivative · entry 3 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,989 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 20:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 2,400 | $15.00 | $36,000.00 |
DisclosureSEC source: 0001209191-23-024979 · doc4.xml · nonDerivative · entry 2 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 20:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 3,000 | $6.28 | $18,840.00 |
DisclosureSEC source: 0001209191-23-024979 · doc4.xml · nonDerivative · entry 1 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 23:35 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023046 · doc4.xml · derivative · entry 4 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,350 Underlying: Common Stock · 3,000 shares Expires 2032-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 23:35 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 402 | $31.17 | $12,531.18 |
DisclosureSEC source: 0001209191-23-023046 · doc4.xml · nonDerivative · entry 3 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,589 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022. F3 · price: Represents the weighted average share price of an aggregate total of 402 shares sold in the price range of $31.09 to $31.18 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 23:35 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 2,598 | $30.63 | $79,589.47 |
DisclosureSEC source: 0001209191-23-023046 · doc4.xml · nonDerivative · entry 2 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,991 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 2,598 shares sold in the price range of $30.09 to $30.91 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 23:35 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 3,000 | $15.00 | $45,000.00 |
DisclosureSEC source: 0001209191-23-023046 · doc4.xml · nonDerivative · entry 1 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 00:26 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 6,966 | $30.77 | $214,333.37 |
DisclosureSEC source: 0001209191-23-008173 · doc4.xml · nonDerivative · entry 2 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,589 F2 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| February 07, 2023 Filed Feb 10, 2023 00:26 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionRestricted Stock Unit · Derivative | 22,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008173 · doc4.xml · derivative · entry 3 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,111 Underlying: Common Stock · 22,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean February 7, 2022. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean February 7, 2022. Read SEC document |
| February 07, 2023 Filed Feb 10, 2023 00:26 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 22,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008173 · doc4.xml · nonDerivative · entry 1 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 19:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 855 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007471 · doc4.xml · derivative · entry 5 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,350 Underlying: Common Stock · 855 shares Expires 2032-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 19:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 400 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001209191-23-007471 · doc4.xml · derivative · entry 4 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,223 Underlying: Common Stock · 400 shares Expires 2031-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 19:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 1,255 | $35.11 | $44,068.07 |
DisclosureSEC source: 0001209191-23-007471 · doc4.xml · nonDerivative · entry 3 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 1,255 shares sold in the price range of $35.04 to $35.27 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 19:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 855 | $15.00 | $12,825.00 |
DisclosureSEC source: 0001209191-23-007471 · doc4.xml · nonDerivative · entry 2 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 19:09 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 400 | $6.28 | $2,512.00 |
DisclosureSEC source: 0001209191-23-007471 · doc4.xml · nonDerivative · entry 1 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:46 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001902 · doc4.xml · derivative · entry 5 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,205 Underlying: Common Stock · 2,500 shares Expires 2032-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:46 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantRestricted Stock Unit · Derivative | 49,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001902 · doc4.xml · derivative · entry 4 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,558 Underlying: Common Stock · 49,558 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 3, 2023. F4 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following the RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean January 3, 2023. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:46 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 76,242 | $0.00 Strike: $31.03 | $0.00 |
DisclosureSEC source: 0001209191-23-001902 · doc4.xml · derivative · entry 3 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,242 Underlying: Common Stock · 76,242 shares Expires 2033-01-03 F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Vesting Commencement Date" shall mean January 1, 2023. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:46 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 2,500 | $31.11 | $77,775.00 |
DisclosureSEC source: 0001209191-23-001902 · doc4.xml · nonDerivative · entry 2 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:46 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 2,500 | $15.00 | $37,500.00 |
DisclosureSEC source: 0001209191-23-001902 · doc4.xml · nonDerivative · entry 1 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 22:16 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061276 · doc4.xml · derivative · entry 5 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,705 Underlying: Common Stock · 7,500 shares Expires 2032-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 22:16 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001209191-22-061276 · doc4.xml · derivative · entry 4 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,623 Underlying: Common Stock · 5,000 shares Expires 2031-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 22:16 UTC | Arcellx, Inc. ACLX · Entity 15294 | SaleCommon Stock | 12,500 | $30.03 | $375,320.00 |
DisclosureSEC source: 0001209191-22-061276 · doc4.xml · nonDerivative · entry 3 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022. F2 · price: Represents the weighted average share price of an aggregate total of 12,500 shares sold in the price range of $30.00 to $30.24 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 22:16 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 7,500 | $15.00 | $112,500.00 |
DisclosureSEC source: 0001209191-22-061276 · doc4.xml · nonDerivative · entry 2 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 22:16 UTC | Arcellx, Inc. ACLX · Entity 15294 | Exercise / conversionCommon Stock | 5,000 | $6.28 | $31,400.00 |
DisclosureSEC source: 0001209191-22-061276 · doc4.xml · nonDerivative · entry 1 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:15 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $19.97 | $0.00 |
DisclosureSEC source: 0001209191-22-051632 · doc4.xml · derivative · entry 1 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-09-28 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following the Vesting Start Date on the same day of the month as the Vesting Start Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Vesting Start Date" shall mean January 1, 2023. Read SEC document |
| February 07, 2022 Filed Feb 7, 2022 22:57 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantRestricted Stock Unit · Derivative | 67,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007560 · doc4.xml · derivative · entry 2 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,666 Underlying: Common Stock · 67,666 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean February 7, 2022. F3 · derivative.expiration_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the RSUs subject to the award will vest each year following RSU Grant Date on the same day of the month as the RSU Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "RSU Grant Date" shall mean February 7, 2022. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 22:57 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 260,205 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007560 · doc4.xml · derivative · entry 1 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,205 Underlying: Common Stock · 260,205 shares Expires 2032-02-03 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 133,206 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0001209191-20-035569 · doc4.xml · derivative · entry 1 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,206 Underlying: Common Stock · 133,206 shares Expires 2030-06-07 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on April 1, 2021 and vests in equal installments at the end of each successive three-month period over the 36 months following such date. Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 21:44 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | PurchaseCommon Stock | 2,235 | $12.08 | $26,998.80 |
DisclosureSEC source: 0001209191-19-061581 · doc4.xml · nonDerivative · entry 2 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,485 Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 21:44 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | PurchaseCommon Stock | 250 | $12.09 | $3,022.50 |
DisclosureSEC source: 0001209191-19-061581 · doc4.xml · nonDerivative · entry 1 Heery Christopher · CIK 0001789632 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.